Sunshine Biopharma (OTCMKTS:SBFM) is gaining momentum on Tuesday as the stock soared on high volume. The stock has gained a lot of attention since the beginning of this year. The stock has moved all the way from 2 cents in January to 19 cents a now – 850% jump in almost 5 months.
As of 10:43, SBFM stock soared by 91.50% to $0.19. The stock has seen a total volume with 42.27 million shares – 11X its average volume of 144.54 million. The stock has moved within a range of 0.1100 – 0.2129 after opening the trade at $0.11.
Sunshine Biopharma’s Adva-27a Destroys Cancer Cells Expressing P-glycoprotein, a Marker Present in Over 50% of All Cancer Types
- SBFM announced that it has elucidated the mechanism of action of Adva-27a, the Company’s flagship anticancer drug candidate. Adva-27a has been found to have two activities: (i) evasion of P-glycoprotein, and (ii) inhibition of Topoisomerase II.
- P-glycoprotein is the most often encountered transmembrane efflux protein responsible for multidrug resistance in over 50% of all cancer types. By escaping the efflux pump of P-glycoprotein, Adva-27a is able to accumulate inside cancer cells and destroy them by inhibiting Topoisomerase II, a DNA unwinding enzyme preferentially used by cancer cells to multiply.
- Multidrug resistance is by far the biggest challenge in cancer therapy and P-glycoprotein is the major culprit. A plethora of anticancer drugs that are central to chemotherapeutic regimes are susceptible to the P-glycoprotein efflux activity.
“The implications of this development are vast in the context of cancer therapy as a whole,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “We are excited to soon have a new drug available for cancer sufferers around the world,” he added.